机译:Secukinumab的疗效和安全性,一种完全人的抗白细胞介素-17A单克隆抗体,中度至严重的银屑病性关节炎患者:24周,随机,双盲,安慰剂控制,第二期概念证明 审判
Institute of Infection Immunity and Inflammation University of Glasgow Glasgow United Kingdom;
Medical Department I Rheumatology Charité Campus Benjamin Franklin Berlin Germany;
Rheumazentrum Ruhrgebiet Herne Germany;
Section of Musculoskeletal Disease University of Leeds Leeds Musculoskeletal Biomedical Research;
Department of Rheumatology Leiden University Medical Center Leiden Netherlands;
Musculoskeletal Research Group Newcastle University Newcastle upon Tyne NHS Foundation Trust;
Praxis für Orthop?die Extrakorporale Sto?wellen-Therapie Hamburg Germany;
Department of Rheumatology and Clinical Immunology Sch?n Klinik Hamburg Eilbek Hamburg Germany;
Department of Rheumatology Medizinische Klinik and Poliklinik IV University of Munich Munich;
Translational Medicine-Autoimmunity Novartis Institutes for BioMedical Research WSJ 386.10.48;
Translational Medicine/BMD/MLA China Novartis Institutes for BioMedical Research Shanghai China;
Translational Medicine-Autoimmunity Novartis Institutes for BioMedical Research WSJ 386.10.48;
Translational Medicine-Autoimmunity Novartis Institutes for BioMedical Research WSJ 386.10.48;
Translational Medicine-Autoimmunity Novartis Institutes for BioMedical Research WSJ 386.10.48;
Department of Clinical Immunology and Rheumatology Academic Medical Centre University of;
机译:secukinumab,一种完全的人类抗白介素17A单克隆抗体,在中度至重度银屑病关节炎患者中的疗效和安全性:为期24周,随机,双盲,安慰剂对照,II期概念验证试用
机译:Secukinumab是一种人类抗白介素17A单克隆抗体,可改善活动型银屑病关节炎:使用皮下给药的一项3期随机,多中心,双盲,安慰剂对照研究的24周疗效和安全性数据。
机译:Secukinumab是一种人类抗白介素17A单克隆抗体,在银屑病关节炎患者中使用(未来2):一项随机,双盲,安慰剂对照的3期临床试验
机译:一种双盲,随机期II试验,对健康成人的26岁的26岁群体的疫苗疫苗
机译:鱼油(二十碳五烯酸和二十二碳六烯酸)对急性肺损伤患者的肺和全身炎症的II期,随机,双盲,安慰剂对照试验。
机译:扩展报告:Ixekizumab一种白介素17A特异性单克隆抗体用于治疗初生性活动性银屑病关节炎患者:24周随机双盲安慰剂对照和活性(阿达木单抗)对照期的结果SPIRIT-P1 III期试验
机译:secukinumab,一种完全的人类抗白介素17A单克隆抗体,在中度至重度银屑病关节炎患者中的疗效和安全性:24周,随机,双盲,安慰剂对照,II期概念验证试用